Biomedical

Multi-Target Directed Drug for Alzheimer’s

The technology

Market need

Alzheimer’s disease (AD) is estimated to afflict 4 million people in the US. The current treatments are limited to symptomatic treatment of cognitive function. The main challenge in AD treatment is its apparent multi- factorial nature. This necessitates the progression from single-target drug development to multi-target.

Technology summary

The invention is a series of novel compounds that are useful for the treatment and prevention of Alzheimer’s disease. These compounds target multiple risk factors involved in AD including amyloid-β oligomers (AβO) oxidative stress and biometals and cell membrane/lipid rafts. The multifunctional Aβ oligomerization inhibitors (BMAOIs) strategy targeting CM/LR and other factors involved in the etiology of AD might be an ideal approach to overcome the limits of traditional single-target based approach.

Chart showing AD model and VCU drug reduces A beta O [View Image]Chart showing AD model and increasing concentration of VCU drug reduces oxidative stress [View Image]

Technology status

Please see journal article- Lenhart et al. J. Med. Chem. 2010, 53, 6198–6209.

Download PDF

Benefits:

  • Multi-targeted approach to treat Alzheimer’s disease
  • Studies indicate ligand crosses blood-brain-barrier

Applications:

  • Treatment of Alzheimer’s disease
  • Inhibit amyloid-β oligomers, oxidative stress, biometals and lipid rafts
  • Potential to slow the progression of Alzheimer’s disease
  • Diagnostic Imaging of beta-amyloid plaques

Additional information

Investigators:

Shijun Zhang, Ph.D.

Patent status:

Patent pending: U.S. rights are available - 13/810,826

License status:

This technology is available for licensing to industry for further development and commercialization.

Category:

Biomedical

VCU Tech #:

10-071

Contact us about
this technology

Magdalena K. Morgan, Ph.D.
Licensing Associate
mkmorgan@vcu.edu
(804) 827-6095